British HIV Association guidelines for the treatment of TB/HIV coinfection 2011

Pozniak, A.; Coyne, KM; Miller, R F; Lipman, Marc; Freedman, A.R.; Ormerod, L P; Ma, Jun; Collins, Simon; Lucas, SB

doi:10.1111/j.1468-1293.2011.00954.x

Cited by 121 publications

(128 citation statements)

References 180 publications

(241 reference statements)

Supporting

Mentioning

124

Contrasting

Order By: Relevance

“…Given the high risk of reactivation, treatment of individuals with latent TB infection is also important for TB elimination in Europe [5][6][7][8][9]. Hence, testing and treatment for LTBI in people living with HIV has been recommended by many European national guideline bodies, the British HIV Association (BHIVA), the UK National Institute for Health and Care Excellence (NICE) and the European AIDS Clinical Society (EACS) [5,[10][11][12]. The UK guidelines were both published in 2011, but their testing protocols differ.…”

Section: Introductionmentioning

confidence: 99%

Decreasing cost effectiveness of testing for latent TB in HIV in a low TB incidence area

et al. 2015

View full text Add to dashboard Cite

Testing for latent tuberculosis infection (LTBI) in HIV-infected persons in low tuberculosis (TB) incidence areas is often recommended. Using contemporary, clinical data, we report the yield and cost-effectiveness of testing all HIV attendees, two current UK strategies and no LTBI testing.Economic modelling was performed utilising 10-year follow up data from a large HIV clinical cohort. Outcomes were numbers of cases of active TB and incremental cost per quality-adjusted life year (QALY) gained.Between 2000 and 2010, 256 people were treated for TB/HIV co-infection. 72 (28%) occurred ⩾3 months after HIV diagnosis and may have been prevented by LTBI testing. Between 2000 and 2005, the incremental cost per QALY gained for the British HIV Association (BHIVA) and UK National Institute of Care Excellence (NICE) strategies, and testing all clinic attendees was €6270, €6998 and €33 473, respectively. These rose to €9332, €32 564 and €74 067, respectively, between 2005 and 2010. Probabilistic sensitivity analysis suggested that at a threshold of €24 000 per additional QALY, the most cost-effective strategies would be NICE or testing all in 2000 -2005 and BHIVA during 2005 Both UK testing regimens missed cases but are cost-effective compared with no testing. Using recent data, they all became more expensive, suggesting that alternative or more targeted TB testing strategies must be considered. @ERSpublications Targeted latent TB testing strategies in HIV are cost effective, but lately have become more expensive

show abstract

Section: Introductionmentioning

confidence: 99%

Decreasing cost effectiveness of testing for latent TB in HIV in a low TB incidence area

et al. 2015

View full text Add to dashboard Cite

show abstract

“…This proportion is much greater in Africa, where 79% of all TB/HIV co infections are found [1]. The advent of Highly Active Antiretroviral Therapy (HAART) in the treatment of HIV infection has significantly decreased the incidence of opportunistic infections as well as improved morbidity and mortality among HIV patients [2].…”

Section: Introductionmentioning

confidence: 99%

“…When Hepatotoxicity implies that the liver shows an elevation in Serum Aspartate Amino Transferase (AST) or Alanine Amino Transferase (ALT) level from the normal range (AST = 0-37 and ALT< 41 IU/l) to >3x upper limit of normal in the presence of symptoms, or Serum AST or ALT greater than 5 times the upper limit of normal in the absence of symptoms [1,10]. AST/ALT elevations instead of Alkaline Phosphatase (ALP) elevations favor liver cell necrosis as a mechanism liver cholestasis.…”

Section: Introductionmentioning

confidence: 99%

The Risk of Hepatotoxicity Associated with HAART/Anti-Tb Co-Treatment: A Case Control Study in a Central Ethiopian Referral Hospital

Ayano¹

2014

Fam Med Med Sci Res

View full text Add to dashboard Cite

show abstract

“…In total, 10 studies were included (Figure 1): 1 systematic review (10) , 2 randomized controlled trials (11) (12) , 1 American evidence-based synopsis (13) , and 6 clinical guidelines from different settings -United States of America (14) (15) , United Kingdom (16) (17) , Australia (18) , and WHO (4) . The results of Evidence -based synopsis = 1…”

Section: Introductionmentioning

confidence: 99%

“…UK, 2011 (16) Adults with HIV in an area of low TB prevalence (13) Age > 12 years, with or without HIV, healthy and without ART Rifapentine + isoniazid (maximum 900mg each) once a week for 3 months under DOT Australia, 2012 (18) With and without HIV, any age and pregnant Isoniazid (300 mg/day) for 9 months (first line and pregnant women)…”

mentioning

confidence: 99%

Rifapentine for latent tuberculosis infection treatment in the general population and human immunodeficiency virus-positive patients: summary of evidence

Vidal

Silva

Sanchez

2015

Rev. Soc. Bras. Med. Trop.

View full text Add to dashboard Cite

Latent tuberculosis infection (LTBI) and human immunodefi ciency virus (HIV)-coinfection are challenges in the control of tuberculosis transmission. We aimed to assess and summarize evidence available in the literature regarding the treatment of LTBI in both the general and HIV-positive population, in order to support decision making by the Brazilian Tuberculosis Control Program for LTBI chemoprophylaxis. We searched MEDLINE, Cochrane Library, Centre for Reviews and Dissemination, Embase, LILACS, SciELO, Trip database, National Guideline Clearinghouse, and the Brazilian Theses Repository to identify systematic reviews, randomized clinical trials, clinical guidelines, evidence-based synopses, reports of health technology assessment agencies, and theses that investigated rifapentine and isoniazid combination compared to isoniazid monotherapy. We assessed the quality of evidence from randomized clinical trials using the Jadad Scale and recommendations from other evidence sources using the Grading of Recommendations, Assessment, Development, and Evaluations approach. The available evidence suggests that there are no differences between rifapentine + isoniazid short-course treatment and the standard 6-month isoniazid therapy in reducing active tuberculosis incidence or death. Adherence was better with directly observed rifapentine therapy compared to self-administered isoniazid. The quality of evidence obtained was moderate, and on the basis of this evidence, rifapentine is recommended by one guideline. Available evidence assessment considering the perspective of higher adherence rates, lower costs, and local peculiarity context might support rifapentine use for LTBI in the general or HIV-positive populations. Since novel trials are ongoing, further studies should include patients on antiretroviral therapy.

show abstract

British HIV Association guidelines for the treatment of TB/HIV coinfection 2011

Cited by 121 publications

References 180 publications

Decreasing cost effectiveness of testing for latent TB in HIV in a low TB incidence area

Decreasing cost effectiveness of testing for latent TB in HIV in a low TB incidence area

The Risk of Hepatotoxicity Associated with HAART/Anti-Tb Co-Treatment: A Case Control Study in a Central Ethiopian Referral Hospital

Rifapentine for latent tuberculosis infection treatment in the general population and human immunodeficiency virus-positive patients: summary of evidence

Contact Info

Product

Resources

About